Advanced/Metastatic Solid Malignancies clinical trials at UC Health
1 research study open to new patients
open to eligible people ages 18 years and up
The study is to evaluate preliminary anti-tumor activity (overall response rate, ORR) of IBI308 monotherapy in subjects with advanced/metastatic solid malignancies. Patients will be recruited for 2 cohorts: Cohort 1: Approximately 60 subjects with advanced/metastatic cancer and high tumor mutational burden (TMB); Cohort 2: 20 subjects with advanced/metastatic endometrial cancer (EC).
at UC Irvine